Skip to content
ReframedNewsLeft · Right · Centered
Quick ReadArchiveAboutSign in
Briefing stories›Science & Climate

FDA approves Pfizer and Arvinas’ Veppanu for certain ESR1-mutated advanced breast cancers

Story date · Friday, May 1, 2026Science & ClimateWell-covered

The facts

  • The FDA approved Veppanu, the breast cancer drug developed by Pfizer and Arvinas, on May 1.
  • Veppanu is approved for adults with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation.
  • The approval applies to patients whose disease has progressed after at least one line of endocrine or hormone therapy.
  • Patients must have the ESR1 mutation identified by an FDA-authorized test to be eligible for treatment.
  • The FDA also approved Guardant360 CDx as a companion diagnostic to identify patients with ESR1-mutated breast cancer who may receive Veppanu.
  • The FDA said its decision was based on the phase 3 VERITAC-2 trial, which enrolled 624 adults with ER-positive, HER2-negative advanced breast cancer.
  • Multiple sources describe Veppanu as the first FDA-approved PROTAC, a type of protein degrader therapy, making the approval notable beyond this specific breast cancer subtype.
  • The approval is limited to a specific subgroup of advanced breast cancer patients, so a remaining practical question is which patients will test positive for ESR1 mutations and qualify under the FDA-authorized diagnostic pathway.

Context

Who can receive Veppanu under the FDA approval?

The drug is approved for adults with ER-positive, HER2-negative advanced or metastatic breast cancer whose tumors have an ESR1 mutation and whose disease has progressed after at least one line of endocrine therapy Reuters,U.S. Food and Drug ….

Why does ESR1 testing matter here?

The FDA approval requires confirmation of an ESR1 mutation using an FDA-authorized test, and the agency also cleared Guardant360 CDx as a companion diagnostic to identify eligible patients Medscape,U.S. Food and Drug …,360Dx.

What makes this approval notable beyond one drug launch?

Several sources say Veppanu is the first FDA-approved PROTAC, a protein degrader therapy, so the decision is also a milestone for that drug-development approach Drugs.com,Healio,BioPharma Dive.

How left and right read it

Left says

The important development is that adults with a hard-defined form of advanced or metastatic breast cancer now have a new FDA-approved option after prior endocrine or hormone therapy has failed. But the approval is tightly tied to an FDA-authorized test, so who actually benefits will depend on whether patients are identified through that diagnostic pathway.

Right says

What stands out here is a regulator approving a genuinely new kind of therapy: Veppanu is described as the first FDA-approved PROTAC, and the decision was grounded in a phase 3 trial involving 624 adults. At the same time, the FDA kept the authorization narrow, limiting use to patients who meet specific disease and testing criteria.

See this differently than someone you know would?

The receipts — 21 sources

Wire services (4)

ReutersReutersUS FDA approves Pfizer, Arvinas' breast cancer drug
Reuters1470 & 100.3 WMBDUS FDA approves Pfizer, Arvinas' breast cancer drug
ReutersU.S. News & World ReportUS FDA Approves Pfizer, Arvinas' Breast Cancer Drug
APMedscapeVepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Other coverage (17)

Drugs.comVeppanu (vepdegestrant) FDA Approval History - Drugs.com
Drugs.comFDA Approves Veppanu (vepdegestrant) for the Treatment of ES...
Investing.com IndiaFDA approves Pfizer-Arvinas breast cancer pill Veppanu for a...
Investing.com IndiaBTIG reiterates Arvinas stock rating on breast cancer drug a...
BioPharma DiveArvinas' 'Protac' breast cancer drug cleared by FDA
FiercePharmaFDA hands Pfizer, Arvinas' Veppanu early approval for breast...
HealioVeppanu earns FDA approval for breast cancer as first proteo...
News Directory 3FDA Approves Vepdegestrant for ESR1-Mutated Advanced Breast ...
360DxPfizer, Arvinas Veppanu, Guardant Health CDx FDA Approved fo...
Investing.com IndiaArvinas shares gain as FDA approves breast cancer drug Veppa...
The Manila timesArvinas Announces FDA Approval of VEPPANU (vepdegestrant) fo...
wallstreet:onlineArvinas Announces FDA Approval of VEPPANU (vepdegestrant) fo...
Investing.com South AfricaFDA approves Arvinas' vepdegestrant for breast cancer treatm...
StockwatchStockwatch
Barchart.comArvinas Announces FDA Approval of VEPPANU (vepdegestrant) fo...
U.S. Food and Drug AdministrationFDA approves vepdegestrant for ER-positive, HER2-negative, E...
MedPage TodayFirst-in-Class Vepdegestrant Approved in Advanced Breast Can...

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

← Earlier in this briefing
Trump says U.S. will raise tariffs on EU cars and trucks to 25% next week
President Donald Trump said Friday that the United States will raise tariffs on cars and trucks imported from the...
Business & Markets
Next in this briefing →
FDA authorizes expanded access program for investigational pancreatic cancer dru...
The FDA said it has authorized Revolution Medicines to begin an expanded access program for daraxonrasib, an...
Science & Climate

Continue Reading

Related this week

Canada pledges up to C$560 million to Brazilian-led tropical forest fund

Canada pledged up to C$560 million (US$392.5 million) over four years to the Brazilian-led Tropical Forests Forever...

Science & Climate
From this briefing

Judges have found the Trump administration out of compliance with lower-court orders in dozens of policy cases

An Associated Press review of court records found that since February 2025, federal district judges have ruled that the...

U.S. Politics
Back to all stories

A news briefing built to show both sides.

The day’s biggest stories in one short brief, built to show both sides and the competing values behind the headlines. Free in your inbox.

ReframedNews

A daily news briefing on the day’s top stories, built to show both sides.

Written by AI from news reporting. We review published briefings. Who writes this →

Navigate

Quick ReadArchiveSettings

Company

AboutHow it worksSkylark CreationsSign InTerms of ServicePrivacy Policy

© 2026 Reframed.News

Made by Skylark Creations